Ex-vivo α-Galactosylceramide activation of NKT cells in humans and macaques

Journal of Immunological Methods

Volumn 382, Issue 1-2, 2012, Pages 150-159

  Fernandez, Caroline S ^a   Cameron, Garth ^a   Godfrey, Dale I ^a   Kent, Stephen J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Galactosylceramide; Macaques; NKT cells; Optimization of ex vivo activation; SIV infection

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; GAMMA INTERFERON; INTERLEUKIN 2; IONOMYCIN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; TUMOR NECROSIS FACTOR;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOTHERAPY; MACACA; MALE; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; UPREGULATION;

ADULT; ANIMALS; FEMALE; GALACTOSYLCERAMIDES; HUMANS; MACACA NEMESTRINA; MALE; MIDDLE AGED; NATURAL KILLER T-CELLS; YOUNG ADULT;

MACACA; MACACA NEMESTRINA; MUS; PRIMATES; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 84863568865     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2012.05.019     Document Type: Article

References (44)

1. Benlagha K., Weiss A., Beavis A., Teyton L., Bendelac A. In vivo identification of glycolipid antigen-specific T cells using fluorescent CD1d tetramers. J. Exp. Med. 2000, 191:1895.
2. Brigl M., Brenner M.B. How invariant natural killer T cells respond to infection by recognizing microbial or endogenous lipid antigens. Semin. Immunol. 2010, 22:79.
3. Cerundolo V., Silk J.D., Masri S.H., Salio M. Harnessing invariant NKT cells in vaccination strategies. Nat. Rev. Immunol. 2009, 9:28.
4. Chang D.H., Osman K., Connolly J., Kukreja A., Krasovsky J., Pack M., Hutchinson A., Geller M., Liu N., Annable R., Shay J., Kirchhoff K., Nishi N., Ando Y., Hayashi K., Hassoun H., Steinman R.M., Dhodapkar M.V. Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J. Exp. Med. 2005, 201:1503.
5. Dale C.J., De Rose R., Stratov I., Chea S., Montefiori D.C., Thomson S., Ramshaw I.A., Coupar B.E., Boyle D.B., Law M., Kent S.J. Efficacy of DNA and fowlpox virus priming/boosting vaccines for simian/human immunodeficiency virus. J. Virol. 2004, 78:13819.
6. Eger K.A., Sundrud M.S., Motsinger A.A., Tseng M., Van Kaer L., Unutmaz D. Human natural killer T cells are heterogeneous in their capacity to reprogram their effector functions. PLoS One 2006, 1:e50.
7. Emoto M., Emoto Y., Yoshizawa I., Kita E., Shimizu T., Hurwitz R., Brinkmann V., Kaufmann S.H.E. Alpha-GalCer ameliorates listeriosis by accelerating infiltration of Gr-1+ cells into the liver. Eur. J. Immunol. 2010, 40:1328.
8. Exley M., Garcia J., Balk S.P., Porcelli S. Requirements for CD1d recognition by human invariant Valpha24+ CD4-CD8- T cells. J. Exp. Med. 1997, 186:109.
9. Fernandez C.S., Chan A.C., Kyparissoudis K., De Rose R., Godfrey D.I., Kent S.J. Peripheral NKT cells in simian immunodeficiency virus-infected macaques. J. Virol. 2009, 83:1617.
10. Fujii S., Shimizu K., Smith C., Bonifaz L., Steinman R.M. Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J. Exp. Med. 2003, 198:267.
11. Fujii S., Motohashi S., Shimizu K., Nakayama T., Yoshiga Y., Taniguchi M. Adjuvant activity mediated by iNKT cells. Semin. Immunol. 2010, 22:97.
12. Gansuvd B., Hubbard W.J., Hutchings A., Thomas F.T., Goodwin J., Wilson S.B., Exley M.A., Thomas J.M. Phenotypic and functional characterization of long-term cultured rhesus macaque spleen-derived NKT cells. J. Immunol. 2003, 171:2904.
13. Giaccone G., Punt C.J., Ando Y., Ruijter R., Nishi N., Peters M., von Blomberg B.M., Scheper R.J., van der Vliet H.J., van den Eertwegh A.J., Roelvink M., Beijnen J., Zwierzina H., Pinedo H.M. A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin. Cancer Res. 2002, 8:3702.
14. Godfrey D.I., Stankovic S., Baxter A.G. Raising the NKT cell family. Nat. Immunol. 2010, 11:197.
15. Guillonneau C., Mintern J.D., Hubert F.X., Hurt A.C., Besra G.S., Porcelli S., Barr I.G., Doherty P.C., Godfrey D.I., Turner S.J. Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:3330.
16. Gumperz J.E., Miyake S., Yamamura T., Brenner M.B. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J. Exp. Med. 2002, 195:625.
17. Hong S., Wilson M.T., Serizawa I., Wu L., Singh N., Naidenko O.V., Miura T., Haba T., Scherer D.C., Wei J., Kronenberg M., Koezuka Y., Van Kaer L. The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat. Med. 2001, 7:1052.
18. Kawano T., Cui J., Koezuka Y., Toura I., Kaneko Y., Motoki K., Ueno H., Nakagawa R., Sato H., Kondo E., Koseki H., Taniguchi M. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 1997, 278:1626.
19. Klatt N.R., Vinton C.L., Lynch R.M., Canary L.A., Ho J., Darrah P.A., Estes J.D., Seder R.A., Moir S.L., Brenchley J.M. SIV infection of rhesus macaques results in dysfunctional T- and B-cell responses to neo and recall Leishmania major vaccination. Blood 2011, 118:5803.
20. Kunii N., Horiguchi S., Motohashi S., Yamamoto H., Ueno N., Yamamoto S., Sakurai D., Taniguchi M., Nakayama T., Okamoto Y. Combination therapy of in vitro-expanded natural killer T cells and alpha-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma. Cancer Sci. 2009, 100:1092.
21. Kuylenstierna C., Bjorkstrom N.K., Andersson S.K., Sahlstrom P., Bosnjak L., Paquin-Proulx D., Malmberg K.J., Ljunggren H.G., Moll M., Sandberg J.K. NKG2D performs two functions in invariant NKT cells: direct TCR-independent activation of NK-like cytolysis and co-stimulation of activation by CD1d. Eur. J. Immunol. 2011, 41:1913.
22. Lindqvist M., Persson J., Thorn K., Harandi A.M. The mucosal adjuvant effect of alpha-galactosylceramide for induction of protective immunity to sexually transmitted viral infection. J. Immunol. 2009, 182:6435.
23. Matsuda J.L., Naidenko O.V., Gapin L., Nakayama T., Taniguchi M., Wang C.R., Koezuka Y., Kronenberg M. racking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. JOURNAL OF EXPERIMENTAL MEDICINE; SEP 4 2000, 192(5):741-753.
24. McElrath M.J., De Rosa S.C., Moodie Z., Dubey S., Kierstead L., Janes H., Defawe O.D., Carter D.K., Hural J., Akondy R., Buchbinder S.P., Robertson M.N., Mehrotra D.V., Self S.G., Corey L., Shiver J.W., Casimiro D.R. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008, 372:1894.
25. Moll M., Kuylenstierna C., Gonzalez V.D., Andersson S.K., Bosnjak L., Sonnerborg A., Quigley M.F., Sandberg J.K. Severe functional impairment and elevated PD-1 expression in CD1d-restricted NKT cells retained during chronic HIV-1 infection. Eur. J. Immunol. 2009, 39:902.
26. Motohashi S., Nagato K., Kunii N., Yamamoto H., Yamasaki K., Okita K., Hanaoka H., Shimizu N., Suzuki M., Yoshino I., Taniguchi M., Fujisawa T., Nakayama T. A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer. J. Immunol. 2009, 182:2492.
27. Novak J., Lehuen A. Mechanism of regulation of autoimmunity by iNKT cells. CYTOKINE; MAR 2011, 53(3):263-270.
28. Nylander S., Kalies I. Brefeldin A, but not monensin, completely blocks CD69 expression on mouse lymphocytes: efficacy of inhibitors of protein secretion in protocols for intracellular cytokine staining by flow cytometry. J. Immunol. Methods 1999, 224:69.
29. O'Neil-Andersen N.J., Lawrence D.A. Differential modulation of surface and intracellular protein expression by T cells after stimulation in the presence of monensin or brefeldin A. Clin. Diagn. Lab. Immunol. 2002, 9:243.
30. Patel O., Cameron G., Pellicci D.G., Liu Z., Byun H.S., Beddoe T., McCluskey J., Franck R.W., Castano A.R., Harrak Y., Llebaria A., Bittman R., Porcelli S.A., Godfrey D.I., Rossjohn J. NKT TCR recognition of CD1d-alpha-C-galactosylceramide. J. Immunol. 2011, 187:4705.
31. Rout N., Else J.G., Yue S., Connole M., Exley M.A., Kaur A. Paucity of CD4+ natural killer T (NKT) lymphocytes in sooty mangabeys is associated with lack of NKT cell depletion after SIV infection. PLoS One 2010, 5:e9787.
32. Sandberg J.K., Fast N.M., Palacios E.H., Fennelly G., Dobroszycki J., Palumbo P., Wiznia A., Grant R.M., Bhardwaj N., Rosenberg M.G., Nixon D.F. Selective loss of innate CD4(+) V alpha 24 natural killer T cells in human immunodeficiency virus infection. J. Virol. 2002, 76:7528.
33. Schneiders F.L., Scheper R.J., von Blomberg B.M., Woltman A.M., Janssen H.L., van den Eertwegh A.J., Verheul H.M., de Gruijl T.D., van der Vliet H.J. Clinical experience with alpha-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B/C infection. Clin. Immunol. 2011, 140:130.
34. Schuerwegh A.J., Stevens W.J., Bridts C.H., De Clerck L.S. Evaluation of monensin and brefeldin A for flow cytometric determination of interleukin-1 beta, interleukin-6, and tumor necrosis factor-alpha in monocytes. Cytometry 2001, 46:172.
35. Snyder-Cappione J.E., Loo C.P., Carvalho K.I., Kuylenstierna C., Deeks S.G., Hecht F.M., Rosenberg M.G., Sandberg J.K., Kallas E.G., Nixon D.F. Lower cytokine secretion ex vivo by natural killer T cells in HIV-infected individuals is associated with higher CD161 expression. AIDS 2009, 23:1965.
36. Sullivan B.A., Nagarajan N.A., Wingender G., Wang J., Scott I., Tsuji M., Franck R.W., Porcelli S.A., Zajonc D.M., Kronenberg M. Mechanisms for glycolipid antigen-driven cytokine polarization by Valpha14i NKT cells. J. Immunol. 2010, 184:141.
37. Uchida T., Horiguchi S., Tanaka Y., Yamamoto H., Kunii N., Motohashi S., Taniguchi M., Nakayama T., Okamoto Y. Phase I study of alpha-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer. Cancer Immunol. Immunother. 2008, 57:337.
38. Uldrich A.P., Crowe N.Y., Kyparissoudis K., Pellicci D.G., Zhan Y., Lew A.M., Bouillet P., Strasser A., Smyth M.J., Godfrey D.I. NKT cell stimulation with glycolipid antigen in vivo: costimulation-dependent expansion, Bim-dependent contraction, and hyporesponsiveness to further antigenic challenge. J. Immunol. 2005, 175:3092.
39. van der Vliet H.J., von Blomberg B.M., Hazenberg M.D., Nishi N., Otto S.A., van Benthem B.H., Prins M., Claessen F.A., van den Eertwegh A.J., Giaccone G., Miedema F., Scheper R.J., Pinedo H.M. Selective decrease in circulating V alpha 24+V beta 11+ NKT cells during HIV type 1 infection. J. Immunol. 2002, 168:1490.
40. Venkataswamy M.M., Porcelli S.A. Lipid and glycolipid antigens of CD1d-restricted natural killer T cells. Semin. Immunol. 2010, 22:68.
41. Vivier E., Ugolini S., Blaise D., Chabannon C., Brossay L. Targeting natural killer cells and natural killer T cells in cancer. Nat. Rev. Immunol. 2012, 12:239.
42. Wilson M.T., Johansson C., Olivares-Villagomez D., Singh A.K., Stanic A.K., Wang C.R., Joyce S., Wick M.J., Van Kaer L. The response of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansion. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:10913.
43. Wu L., Van Kaer L. Natural killer T cells and autoimmune disease. Curr. Mol. Med. 2009, 9:4.
44. Yamasaki K., Horiguchi S., Kurosaki M., Kunii N., Nagato K., Hanaoka H., Shimizu N., Ueno N., Yamamoto S., Taniguchi M., Motohashi S., Nakayama T., Okamoto Y. Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy. Clin. Immunol. 2011, 138:255.